Your Menopause Treatment Options: Step One — Should You Treat at All?
When you start looking at menopause treatment options for the first time, the volume of information can feel paralyzing. Hormone therapy, non-hormonal drugs, natural supplements, lifestyle changes — each path has its own evidence base, cost profile, and risk calculation. The threshold for treatment is personal, but there are objective measures that help. The Menopause-Specific Quality of Life questionnaire (MENQOL) and the Hot Flash Related Daily Interference Scale are both validated tools that clinicians use. A woman scoring above 4 on any MENQOL domain — meaning symptoms interfere moderately to extremely — is a candidate for treatment. The practical version of this is simpler: if your hot flashes happen more than seven times per day, if you wake up drenched more than twice per night, or if you avoid social situations because of flushing, you have moved past the “wait and see” window. The 2024 NICE guideline update on menopause explicitly states that symptom severity, not lab values, should drive treatment decisions. Roughly 20 percent of women pass through menopause with minimal disruption. Another 60 percent have moderate symptoms that may or may not warrant intervention. The remaining 20 percent experience severe symptoms — and for them, treating is not optional, it is survival. A 2024 survey from the British Menopause Society found that women who delayed treatment for more than two years of severe symptoms were significantly more likely to report depression and anxiety at follow-up, suggesting that “waiting it out” has a real psychological cost. If your hot flashes wake you more than twice per night, if your mood swings feel uncontrollable, or if vaginal dryness makes sex painful to the point of avoidance, you are in the treat-now category. If your symptoms are mild and intermittent, the evidence supports watchful waiting with lifestyle support.
Step Two: Can You Take Hormones?
This is the fork in the road that determines your entire treatment map. Hormone therapy remains the most effective treatment for vasomotor symptoms — roughly 80 to 90 percent of women get significant relief. But not every woman can or should take estrogen. The absolute contraindications include a personal history of hormone-sensitive breast cancer, active liver disease, unexplained vaginal bleeding, and a history of venous thromboembolism (blood clots) not related to surgery or temporary risk factors. Relative contraindications include migraine with aura, a strong family history of breast cancer with known BRCA mutations, and some forms of endometrial cancer.
Should you take HRT? is the most common question women ask, and the answer depends on timing. The “window of opportunity” concept — start hormone therapy within 10 years of menopause and before age 60 — is supported by the 2024 International Menopause Society updated guidelines. Starting after age 60 or more than a decade past menopause shifts the risk-benefit ratio, particularly for cardiovascular events. If you are under 60 and within 10 years of menopause with no contraindications, the evidence strongly favors treatment. If you fall outside that window, your options tilt toward the non-hormonal list.
Step Three: If You Can Take Hormones, Which Delivery Is Right for You?
Estrogen is estrogen is estrogen — except it is not. The route of delivery changes the safety profile substantially. Transdermal estrogen (patches, gel, spray) bypasses the liver’s first-pass metabolism, which means it carries essentially no increased risk of blood clots. Oral estrogen goes through the liver and activates clotting factors, which is why the WHI showed a VTE risk increase for oral but not transdermal. For a woman with any vascular risk factor — obesity, smoking, a family history of clots — the default should be transdermal delivery.
Menopause HRT options include patches changed once or twice weekly, daily gel that you apply to your arm or thigh, a spray that you apply once daily, implants lasting four to six months, and the vaginal ring (Femring) that delivers both systemic and local estrogen. The choices can feel overwhelming, but the decision framework is simple. If you have a uterus, you need progesterone or progestin alongside estrogen to protect the endometrium. That progesterone can be oral (micronized progesterone at 100 to 200 milligrams daily cycling or continuously) or an intrauterine device like Mirena. If you had a hysterectomy, you can take estrogen alone — no progesterone needed. Among women who choose transdermal estrogen, patches are the most popular choice in the United States, while gel dominates in Europe. A 2025 survey of 4,000 women across both continents showed no difference in symptom relief between patches and gel, only in convenience and skin reactions.
Step Four: If You Cannot Take Hormones, Which Non-Hormonal Path Fits Best?
For women with contraindications to estrogen, the menu has expanded dramatically in the past three years. The NK3 receptor antagonists — Veozah (fezolinetant) and Lynkuet (elinzanetant) — are the first-line non-hormonal option for moderate to severe hot flashes, with clinical trial data showing 60 to 70 percent reduction in frequency. If cost is a concern (roughly $550 per month in the US), an SSRI like venlafaxine at 37.5 to 75 milligrams daily is the cheaper alternative and will cost around $20 to $40 per month on generic pricing. Gabapentin at 300 to 900 milligrams daily, titrated up over two weeks, is another solid option, especially for women with sleep disruption or migraine.
Oxybutynin at 2.5 to 5 milligrams works well for hot flashes — one 2021 meta-analysis in Menopause showed a 64 percent reduction — but the anticholinergic load gives many clinicians pause, especially for women over 65. The 2025 British Menopause Society non-hormonal treatment consensus recommends oxybutynin as a second-line option behind NK3 antagonists and SSRIs/SNRIs. Clonidine remains available but produces only a 20 to 30 percent reduction with a high side-effect burden, and it occupies the bottom of the evidence hierarchy for pharmacologic options.
Step Five: What About Natural Options and Doing Nothing?
Natural menopause treatment has real appeal: no prescriptions, no doctor visits, no drug side effects. The evidence, however, does not match the enthusiasm. Soy isoflavones at 50 to 100 milligrams daily reduce hot flashes by roughly 15 to 25 percent — better than nothing but not close to what medications achieve. Black cohosh failed to beat placebo in the NIH-funded HALT trial led by Dr. Katherine Newton at Group Health Cooperative. Red clover, evening primrose oil, and dong quai have similarly weak or absent evidence in randomized trials. The herbal market for menopause is a multi-billion-dollar industry built on expectation bias and small, poorly controlled studies.
The lifestyle interventions that do have data — paced breathing, weight loss, avoiding alcohol and caffeine triggers — are free and carry no risk, and should be the foundation of any plan, with or without medication. A 2015 trial from the MsFLASH network found that a structured yoga program improved sleep quality but did not reduce hot flash frequency. A 2024 systematic review in Climacteric found that resistance training improved both body composition and hot flash bother in postmenopausal women. These effects are additive. A woman who combines paced breathing, weight management, and trigger avoidance may achieve a 30 to 40 percent reduction in symptom bother — enough to make mild to moderate symptoms tolerable without drugs.
Doing nothing is a legitimate choice for women with mild symptoms. The 2025 position statement from NAMS explicitly states that “no treatment” is a valid option for women whose symptoms do not interfere with quality of life. But the risk of doing nothing when symptoms are severe is not just discomfort. Uncontrolled hot flashes are associated with worse sleep quality, higher rates of depression, and reduced work productivity costing an estimated $1,800 per woman per year in lost wages according to a 2024 analysis in Menopause journal authored by Dr. Risa Kagan and colleagues. Untreated menopause also accelerates bone density loss at a rate of 1 to 2 percent per year in the first five years after the final menstrual period, increasing the lifetime risk of osteoporotic fracture. And cardiovascular risk rises more steeply after menopause, with the American Heart Association recognizing menopause as a cardiovascular risk-milestone event in its 2024 scientific statement.
Cost, Time Commitment, and Risk Profiles Compared
The price differences between treatment paths are stark. Generic estrogen patches cost roughly $30 to $60 per month without insurance in the US. Micronized progesterone adds another $20 to $40. Veozah and Lynkuet run $500 to $600 per month, though manufacturer copay assistance programs can drop that to $10 to $50 for eligible patients. Generic venlafaxine costs about $15 to $30. Gabapentin is similar. Black cohosh supplements at the grocery store cost $10 to $20 but deliver essentially no effect.
Time commitment varies too. A daily pill or patch is a 30-second habit. CBT requires six weekly hour-long sessions. The NK3 drugs require quarterly liver function monitoring for the first 12 months. Oxybutynin requires cognitive baseline screening for women over 65. The risk profiles also diverge: hormone therapy increases breast cancer risk slightly after five-plus years of combined use (about 8 extra cases per 10,000 women per year in the WHI), SSRIs reduce sexual function in 20 to 30 percent of users, gabapentin causes sedation and unsteadiness, and oxybutynin carries a dementia signal in long-term population studies. There is no perfect option. There is only the option that matches your medical history, your risk tolerance, and your symptom burden.
The decision guide in a single line: start with the most effective option that your medical history allows, add lifestyle support as a foundation, and be willing to switch if the first choice does not work. The average woman tries two to three different treatments before finding the one that fits, and that is normal.